

Juan Carlos Carril

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3908354/publications.pdf>

Version: 2024-02-01

20
papers

561
citations

686830

13
h-index

839053

18
g-index

20
all docs

20
docs citations

20
times ranked

485
citing authors

#	ARTICLE	IF	CITATIONS
1	Personalized Management and Treatment of Alzheimer's Disease. <i>Life</i> , 2022, 12, 460.	1.1	4
2	Influence of Pathogenic and Metabolic Genes on the Pharmacogenetics of Mood Disorders in Alzheimer's Disease. <i>Pharmaceuticals</i> , 2021, 14, 366.	1.7	6
3	Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics. <i>Medicinal Research Reviews</i> , 2021, 41, 2841-2886.	5.0	7
4	Influence of dopamine, noradrenaline, and serotonin transporters on the pharmacogenetics of Atremorine in Parkinson's disease. <i>Drug Development Research</i> , 2021, 82, 695-706.	1.4	3
5	Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13302.	1.8	25
6	DNA Methylation in Neurodegenerative and Cerebrovascular Disorders. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2220.	1.8	44
7	Genomics and Pharmacogenomics of Rhinosinusitis. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2020, 17, 114-124.	0.2	0
8	The Epigenetic Machinery in the Life Cycle and Pharmacoepigenetics. , 2019, , 1-100.		9
9	Sirtuins in Alzheimer's Disease: SIRT2-Related GenoPhenotypes and Implications for PharmacoEpiGenetics. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1249.	1.8	64
10	The role of pharmacogenomics in adverse drug reactions. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 407-442.	1.3	71
11	Pharmacogenetics of Vascular Risk Factors in Alzheimer's Disease. <i>Journal of Personalized Medicine</i> , 2018, 8, 3.	1.1	28
12	Pharmacogenetics of Neurodegenerative disorders. <i>Internal Medicine Review (Washington, D C:)</i> Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 3	0.3	2
13	Optimization of Antidepressant Use with Pharmacogenetic Strategies. <i>Current Genomics</i> , 2017, 18, 442-449.	0.7	23
14	Pharmacogenetic considerations in the treatment of Alzheimer's disease. <i>Pharmacogenomics</i> , 2016, 17, 1041-1074.	0.6	39
15	Can cloud-based tools accelerate Alzheimer's disease drug discovery?. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 215-223.	2.5	21
16	Novel Therapeutic Strategies for Dementia. <i>CNS and Neurological Disorders - Drug Targets</i> , 2016, 15, 141-241.	0.8	42
17	Pharmacogenomics of Alzheimer's Disease: Novel Therapeutic Strategies for Drug Development. <i>Methods in Molecular Biology</i> , 2014, 1175, 323-556.	0.4	60
18	Genomics and Pharmacogenomics of Brain Disorders. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 674-725.	0.9	32

#	ARTICLE	IF	CITATIONS
19	Genomics of Dementia:APOE- andCYP2D6-Related Pharmacogenetics. International Journal of Alzheimer's Disease, 2012, 2012, 1-37.	1.1	44
20	Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants. Pharmaceuticals, 2010, 3, 3040-3100.	1.7	37